PRF Technologies (PRFX) Short term Debt (2019 - 2020)

PRF Technologies (PRFX) posted quarterly Short term Debt of $1.5 million for Q2 2020, up 40.7% on a QoQ basis from $1.0 million in Q4 2019.

PRF Technologies (PRFX) Short term Debt (2019 - 2020) Analysis & Trends

PRF Technologies (PRFX) has reported Short term Debt for 2 consecutive years, with $1.5 million the latest figure, recorded in Q2 2020.

  • Quarterly Short term Debt changed N/A year-over-year to $1.5 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $1.5 million (changed N/A YoY) and the FY2019 annual result came in at $1.0 million, changed N/A from the prior year.
  • Short term Debt climbed to $1.5 million in Q2 2020 per PRFX's latest filing, from $1.0 million in the prior quarter.
  • Over the last five years, Short term Debt for PRFX reached as high as $1.5 million in Q2 2020 and fell as low as $1.0 million in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 PRF Technologies 745,168.93 451,168.93 -

Historic Data

Download Data
DateValue
Jun 30, 2020 1.45 Mn
Dec 31, 2019 1.03 Mn